ABBVIE INC. vs. Aktis Oncology, Inc. Common stock
ABBVIE INC. (ABBV) comes out ahead, leading on 3 of 3 compared factors.
Size & Scale
| ABBV | AKTS | |
|---|---|---|
| Market Cap | $439.59 billion | $1.33 billion |
| Revenue (TTM) | $64.39 billion | — |
| Net Income (TTM) | $6.32 billion | — |
ABBV leads on 1 of 1 size & scale factors.
Valuation
| ABBV | AKTS | |
|---|---|---|
| P/E Ratio | 70.47 | — |
| Price / Book | -74.66 | 2.62 |
| Price / Sales | 6.83 | — |
ABBV leads on 1 of 1 valuation factors.
Profitability
| ABBV | AKTS | |
|---|---|---|
| Net Margin | 9.81% | — |
| Return on Equity | -107.29% | — |
ABBV and AKTS split the profitability factors evenly.
Dividend
| ABBV | AKTS | |
|---|---|---|
| Dividend Yield | 2.77% | — |
| Payout Ratio | 195.48 | — |
ABBV and AKTS split the dividend factors evenly.
Risk & Sentiment
| ABBV | AKTS | |
|---|---|---|
| Short Interest | 0.85% | 1.68% |
ABBV leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, AKTS overview, AKTS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.